This new approval expands Ozempic’s use, adding to its previous indications for improving glycemic control in Type 2 diabetes and reducing major cardiovascular events in people with heart disease, according to a Jan. 28 news release from Novo Nordisk.
The basis of the approval was due to a phase 3 trial that demonstrated the drug significantly reduced the risk of kidney disease progression and cardiovascular death by 24%, compared to a placebo, over three years.
Ozempic was first approved by the FDA in 2017 for blood sugar control in Type 2 diabetes. It received a cardiovascular indication in 2020 and is now the most broadly indicated GLP-1 receptor agonist for managing diabetes, kidney disease and heart risk.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.